|
SGCE expression based on
|
| Comparison | Statistical significance |
| Normal-vs-Primary | 1.88260518285688E-12 |
|
Note
Cancer stage information is not available for 2 samples.
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Stage1 |
5.12450082368332E-11 |
| Normal-vs-Stage2 |
7.633600E-04 |
| Normal-vs-Stage3 |
1.17361675933125E-12 |
| Normal-vs-Stage4 |
1.58420000451187E-08 |
| Stage1-vs-Stage2 |
7.894400E-01 |
| Stage1-vs-Stage3 |
8.792500E-02 |
| Stage1-vs-Stage4 |
3.106400E-01 |
| Stage2-vs-Stage3 |
5.473200E-01 |
| Stage2-vs-Stage4 |
6.920600E-01 |
| Stage3-vs-Stage4 |
7.882000E-01 |
|
|
Note
Patient race information is not available for 92 samples and one samples from American Indians not included in the above plot.
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Caucasian |
9.97091298415853E-13 |
| Normal-vs-AfricanAmerican |
5.776300E-03 |
| Normal-vs-Asian |
3.875700E-03 |
| Caucasian-vs-AfricanAmerican |
9.409800E-01 |
| Caucasian-vs-Asian |
4.587600E-01 |
| AfricanAmerican-vs-Asian |
6.036000E-01 |
|
|
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Male |
9.11937192427104E-13 |
| Normal-vs-Female |
7.2961636732316E-12 |
| Male-vs-Female |
1.364030E-01 |
|
|
Note
Seventeen samples from patient below 21 years not considered in above plot.
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Age(21-40Yrs) |
2.23770002527601E-10 |
| Normal-vs-Age(41-60Yrs) |
3.09979997226151E-09 |
| Normal-vs-Age(61-80Yrs) |
1.6286971771251E-12 |
| Normal-vs-Age(81-100Yrs) |
8.34189999965318E-07 |
| Age(21-40Yrs)-vs-Age(41-60Yrs) |
7.936000E-01 |
| Age(21-40Yrs)-vs-Age(61-80Yrs) |
5.215200E-03 |
| Age(21-40Yrs)-vs-Age(81-100Yrs) |
2.200000E-01 |
| Age(41-60Yrs)-vs-Age(61-80Yrs) |
3.498300E-03 |
| Age(41-60Yrs)-vs-Age(81-100Yrs) |
6.735900E-02 |
| Age(61-80Yrs)-vs-Age(81-100Yrs) |
8.831200E-01 |
|
|
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Classical-VS-Tall |
1.057980E-02 |
| Classical-VS-Follicular |
8.30240000000426E-05 |
| Classical-VS-Other |
3.340600E-01 |
| Classical-VS-Normal |
2.93090000047513E-08 |
| Tall-VS-Follicular |
3.870600E-01 |
| Tall-VS-Other |
9.813400E-01 |
| Tall-VS-Normal |
1.66110003529951E-09 |
| Follicular-VS-Other |
7.332200E-01 |
| Follicular-VS-Normal |
8.90953977261688E-13 |
| Other-VS-Normal |
4.996000E-04 |
|
|
Note
Cancer in nearby lymph nodes cannot be measured (NX) in 50 samples.
| pathologic_N descriptions |
| N0 | No regional lymph node metastasis |
N1 | Metastases in 1 to 3 axillary lymph nodes |
| N2 | Metastases in 4 to 9 axillary lymph nodes |
N3 | Metastases in 10 or more axillary lymph nodes |
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-N0 |
5.00932628710871E-13 |
| Normal-vs-N1 |
1.9461000000387E-07 |
| N0-vs-N1 |
6.193600E-01 |
|
|
